Georg Andreas Gundersen is CEO of Amicoat. Gundersen brings broad experience from both medicine, science and business. He spent six years at McKinsey & Company before joining Amicoat. He holds an MD and a PhD in Neuroscience from the University of Oslo.
Dr. Svendsen brings extensive research experience in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specializing in antibacterial peptides. Dr. Svendsen received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø. Dr. Svendsen is also a co-founder and board member of Lytix Biopharma AS, a Norwegian pharmaceutical company focusing on cancer immunotherapy.
<strong>Roger Tuen</strong> is Vice President Business Development of Amicoat. Tuen brings broad international experience within the life science industry in commercial, business development and general management positions in listed companies. He has negotiated several license agreements and successfully managed alliances with top-tier pharmaceutical companies on a global level. He holds a MSc Pharm from the University of Oslo and a MBA from the Norwegian School of Management and ESCP-EAP, France.
Kjetil Vangsnes is CFO of Amicoat and is responsible for finance and administration. Vangsnes holds an MBA from INSEAD and an MSc from the Norwegian School of Economics. He brings with him a wide experience from industry, life science, oil services, and shipping. Vangsnes has 20 years experience as CFO in listed and non- listed companies. He has mainly worked in international settings and has experience from Norwegian, US (GE Healthcare) and French (Technip) group constellations. He has held overall financial responsibilities and has been a board member in companies in Norway and abroad.
Dr. Anders Fugelli, PhD is the Vice President of Projects in Amicoat. Dr Fugelli has extensive experience in global product development and strategy from GlaxoSmithKline and Lytix Biopharma AS in Norway. At Lytix Biopharma AS he was initially Head of R&D. He was part of the team that brought two novel drugs to clinical Phase I/II testing within infectious disease and oncology. Later as Head of Business Development he was responsible for a joint venture project with South Korean company KAEL- GemVax and maintained contact with potential biotech and pharma partners. He has served as CEO of a start-up company within neurology, raising capital and driving the project forward to preclinical stage. He holds a PhD in pharmacology / biochemistry from Imperial College, London for work carried out at Pasteur Institute, Paris and Inst. of Preclinical Medicine in Oslo.
Mr. Axelsson received an education in Natural Science and presently serves as CEO in HotSwap AB (Jönköping, Sweden), a company working with product development for international industries. Axelsson brings broad experience with projects in medical equipment and instrumentation, plastics technology, and cost-effective manufacturing processes. Axelsson has long experience as project manager and as board member for various companies. As inventor Mr. Axelsson holds several patents.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
